IL7 and neoplasm: IL-12 was delivered combined with IL-7 by a tumor-selective oncolytic vaccinia virus into tumor-immunocompetent mice [92], anti-tumor activity was observed in all three models tested, with 92.9% tumor growth inhibition in a B16-F10 melanoma model, 53.3% in a CT26.WT colon carcinoma model, and 53.3% in a LLC lung carcinoma model.